TY - JOUR
T1 - MicroRNA regulation of cell viability and drug sensitivity in lung cancer
AU - Du, Liqin
AU - Pertsemlidis, Alexander
N1 - Funding Information:
The authors receive funding from the NIH/NCI through R01 CA 129632 (Awarded to A Pertsemlidis); and from the Greehey Children’s Cancer Research Institute through start-up funds. The authors have no other competing interests to declare.
PY - 2012/9
Y1 - 2012/9
N2 - Introduction: microRNAs (miRNAs) are 19 23 nucleotide long RNAs found in multiple organisms that regulate gene expression and have been shown to play important roles in tumorigenesis. In the context of lung cancer, numerous studies have shown that tumor suppressor genes and oncogenes that play crucial roles in lung tumor development and progression are targets of miRNA regulation. Manipulation of miRNA levels that modulate lung cancer cell survival and drug sensitivity can therefore provide novel therapeutic targets and agents. Areas covered: Here, the authors review the published in vitro, in vivo and preclinical studies on the functional role of miRNAs in modulating lung cancer cell viability and drug response, and discuss the limitations and promise of translating current findings into miRNA-based therapeutic and diagnostic strategies. Expert opinion: Although many miRNAs have been identified as potent regulators of cell viability and drug sensitivity in lung cancer, most of them have not been characterized for potential clinical application. Further study is warranted to evaluate translation of the current findings to the clinic to improve the diagnosis and treatment of lung cancer. In addition, most studies have focused on non-small cell lung cancer (NSCLC). It is therefore important to raise interest in investigating miRNAs in small cell lung cancer (SCLC) as well as in comparative studies of miRNA expression and function in different histological subtypes of lung cancer.
AB - Introduction: microRNAs (miRNAs) are 19 23 nucleotide long RNAs found in multiple organisms that regulate gene expression and have been shown to play important roles in tumorigenesis. In the context of lung cancer, numerous studies have shown that tumor suppressor genes and oncogenes that play crucial roles in lung tumor development and progression are targets of miRNA regulation. Manipulation of miRNA levels that modulate lung cancer cell survival and drug sensitivity can therefore provide novel therapeutic targets and agents. Areas covered: Here, the authors review the published in vitro, in vivo and preclinical studies on the functional role of miRNAs in modulating lung cancer cell viability and drug response, and discuss the limitations and promise of translating current findings into miRNA-based therapeutic and diagnostic strategies. Expert opinion: Although many miRNAs have been identified as potent regulators of cell viability and drug sensitivity in lung cancer, most of them have not been characterized for potential clinical application. Further study is warranted to evaluate translation of the current findings to the clinic to improve the diagnosis and treatment of lung cancer. In addition, most studies have focused on non-small cell lung cancer (NSCLC). It is therefore important to raise interest in investigating miRNAs in small cell lung cancer (SCLC) as well as in comparative studies of miRNA expression and function in different histological subtypes of lung cancer.
KW - Cell viability
KW - Drug response
KW - Drug sensitivity
KW - MicroRNA
KW - Non-small cell lung cancer
KW - Oncogene
KW - Small cell lung cancer
KW - Tumor suppressor gene
UR - http://www.scopus.com/inward/record.url?scp=84865327159&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865327159&partnerID=8YFLogxK
U2 - 10.1517/14712598.2012.697149
DO - 10.1517/14712598.2012.697149
M3 - Review article
C2 - 22731874
AN - SCOPUS:84865327159
SN - 1471-2598
VL - 12
SP - 1221
EP - 1239
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
IS - 9
ER -